Can FGF-1 Enhance Stroke Recovery?
Science Editor Dr. Thomas Glenn and Zhittya Genesis Medicine's Dr. Jack Jacobs.
About Zhittya Genesis Medicine
Zhittya Genesis Medicine is a biotechnology company based in Las Vegas, Nevada. We are seeking to commercialize human FGF-1, a potent, naturally occurring growth factor. Since its discovery in the 1970s, FGF-1 has been extensively studied. Although very promising clinical results were achieved when FGF-1 was administered to patients with severe coronary artery disease and chronic diabetic foot ulcers, efforts to bring FGF-1 to market have largely been abandoned with no additional clinical testing reported since 2009. Zhittya's management believes that FGF-1 has the potential to be a revolutionary new biological drug for the treatment of numerous diseases characterized by a lack of blood flow to an organ or tissue. In fact, there are over 75 human diseases resulting from a lack of blood flow or perfusion to tissues and Zhittya has now targeted 19 of those disorders for treatment with FGF-1.
To view the interview, please visit:
About The Ellis Martin Report
The Ellis Martin Report (TEMR) is an internet based radio program showcasing potentially undervalued companies to an audience of potential retail investors and fund managers that comprise our listening audience. TEMR is broadcasted on the VoiceAmerica Business Channel and The Opportunity Radio Network. CEO and company interviews are paid for by those represented on the program.
The Ellis Martin Report